Valuation: Corbus Pharmaceuticals Holdings, Inc.

Market Cap 170M 149M 139M 127M 239M 16.4B 243M 1.65B 644M 8.04B 638M 624M 27.8B P/E 2026 *
-1.97x
P/E 2027 * -1.73x
Enterprise Value 170M 149M 139M 127M 239M 16.4B 243M 1.65B 644M 8.04B 638M 624M 27.8B EV / Sales 2026 *
153x
EV / Sales 2027 * 70.8x
Free-Float
98.92%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Corbus Pharmaceuticals Holdings, Inc.

1 day-1.61%
1 week+1.78%
Current month-2.24%
1 month+11.15%
3 months-8.85%
6 months+5.04%
Current year+12.65%
1 week 8.73
Extreme 8.73
9.48
1 month 8.5
Extreme 8.5
9.88
Current year 7.12
Extreme 7.12
12.88
1 year 7.12
Extreme 7.12
20.56
3 years 3.03
Extreme 3.0334
61.9
5 years 2.11
Extreme 2.11
61.9
10 years 2.11
Extreme 2.11
323.4
Manager TitleAgeSince
Chief Executive Officer 51 11/04/2014
Director of Finance/CFO 68 11/04/2014
Chief Operating Officer 53 15/03/2025
Director TitleAgeSince
Director/Board Member 51 11/04/2014
Director/Board Member 50 16/08/2024
Director/Board Member 48 13/05/2026
Date Insider Type Main position Quantity % Market Cap.
10/06/26 Sell

Director

-2,412 0.0130%
10/06/26 Sell

Director

-4,800 0.0259%
10/06/26 Sell

Director

-2,026 0.0109%
Change 5-day change 1-year change 3-year change Capi.($)
-1.61%+1.78%-0.97%+39.79% 170M
+0.93%+6.97%+59.60%+68.35% 57.28B
-1.92%+6.03%+40.64%+83.42% 54.99B
-0.46%-1.29%+2.86%+428.78% 23.18B
-2.97%-2.35%-22.53%-16.40% 22.59B
-0.36%+5.73%+24.13%-6.24% 20.46B
-1.34%+0.51%+26.03%-29.41% 17.56B
-1.44%+5.67%+38.77%+504.71% 15.67B
-1.30%-5.02%+170.77%+291.37% 14.46B
-0.50%-0.98%+21.43%+180.07% 13.92B
Average -1.10%+1.33%+36.07%+154.44% 24.03B
Weighted average by Cap. -0.87%+2.10%+39.67%+133.43%

Financials

2026 *2027 *
Net sales 1.11M 975K 907K 832K 1.56M 107M 1.59M 10.77M 4.21M 52.59M 4.17M 4.08M 182M 2.4M 2.11M 1.96M 1.8M 3.38M 232M 3.43M 23.27M 9.09M 114M 9.01M 8.81M 393M
Net income -97.64M -85.69M -79.68M -73.14M -138M -9.43B -140M -947M -370M -4.62B -366M -359M -15.98B -123M -108M -100M -91.95M -173M -11.85B -175M -1.19B -465M -5.81B -461M -451M -20.08B
Net Debt - -
Logo Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company. The Company has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.
Employees
36
Date Price Change Volume
24/07/26 $9.170 -1.61% 172,705
23/07/26 $9.320 +5.43% 639,811
22/07/26 $8.840 -1.56% 154,538
21/07/26 $8.980 +1.01% 80,999
20/07/26 $8.890 -1.33% 209,561
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
9.170USD
Average target price
35.30USD
Spread / Average Target
+284.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRBP Stock